entertainment -WSS

entertainment

author：hotspot 2025-09-29 16:33:11 - browse：242

Intellia Therapeutics said Sunday that the first 10 patients to receive a CRISPR-based treatment for hereditary angioedema, a genetic disease, saw their swelling attacks — the condition’s hallmark symptom — virtually eliminated for an average of 20 months and counting.

The attacks were reduced by an average of 98%. One patient has remained attack-free for 26 months. Two patients who suffered particularly frequent attacks, experiencing 14 and 16.8 per month, respectively, have now gone more than 20 months since their last attack.

No patient has had an attack in the last 11 months of follow-up, according to the data presented at the European Academy of Allergy and Clinical Immunology Congress. All side effects were either grade 1 or 2 on a 5-grade scale.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： There's an unseen cost to disruptive road

WSS

To bolster infectious disease surveillance, genomics powerhouses team up

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Abbott's new stent may help patients with peripheral artery disease

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

Prior authorization reform is both possible and imperative

There's an unseen cost to disruptive road

hotspot

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

As demand for Covid shots wanes, Moderna seeks its next success

Galapagos to make CAR

23andMe had bad news about my health. I wish a person had delivered it

Cardiologists urge adding sexual orientation, gender identity to health records

Cancer drug shortages should be causing more outrage

Obesity drug from Roche shows promise in early study

In age of alternative facts, a scholarly course on calling out crap

Cherokee Nation medical school graduates its first class

Continuity nursing helped my family in our darkest PICU moments

Cherokee Nation medical school graduates its first class

leisure time

Obesity drug from Roche shows promise in early study

Cardiologists urge adding sexual orientation, gender identity to health records

FDA endorses new sterilization method for medical devices

CVS is on a mission to consolidate health care. Will it work?

Medicare bonuses could stop drug shortages under Senate plan

Flu vaccine reformulation won't be easy, manufacturers warn

leisure time

focus

Wikipedia

explore